OncoGenex Pharmaceuticals (ACHV) Earns Daily News Sentiment Score of 0.22

Headlines about OncoGenex Pharmaceuticals (NASDAQ:ACHV) have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.9068446822637 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, ValuEngine upgraded OncoGenex Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th.

OncoGenex Pharmaceuticals (ACHV) opened at $1.18 on Friday. OncoGenex Pharmaceuticals has a 1 year low of $1.17 and a 1 year high of $10.23.

OncoGenex Pharmaceuticals (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter.

COPYRIGHT VIOLATION WARNING: This article was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://weekherald.com/2017/12/15/oncogenex-pharmaceuticals-achv-given-daily-news-impact-score-of-0-22.html.

About OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

Insider Buying and Selling by Quarter for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

Receive News & Ratings for OncoGenex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply